Trending:
News
-
20 July 2018
UNC Lineberger finds new target for kidney cancer
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has discovered a new potential therapeutic target for clear cell renal cell carcinoma (RCC), the most common form of kidney cancer....
-
20 July 2018
Deals this week: Merck, Apotex, Dare Bioscience
Merck has signed a co-development agreement with Xian-Janssen Pharmaceutical to launch its INVOKANA (canagliflozin) drug, which is indicated for the treatment of type 2 diabetes, in China.
-
20 July 2018
EUSA Pharma to acquire Janssen Ireland’s Sylvant for $115m
EUSA Pharma has signed a definitive agreement to purchase global rights for Sylvant (siltuximab) drug from Janssen Sciences Ireland for a cash consideration of $115m.
-
20 July 2018
New report reveals need for more women in P&L roles in pharma industry
A new report by The Pipeline has indicated the need for the appointment of more women in profit and loss (P&L) roles in order to eliminate hindrance to gender diversity...
-
20 July 2018
FDA approves expanded indication for Novartis drug Kisqali
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its Kisqali (ribociclib) to treat advanced or metastatic breast cancer patients who are hormone-receptor positive, human epidermal...
-
19 July 2018
AstraZeneca to stockpile medicines in preparation for no-deal Brexit
UK pharmaceutical company AstraZeneca has announced it increasing its stockpiles of medicines in UK and Europe that could be affected as a result of Brexit by approximately 20% in case...
-
19 July 2018
Novartis postpones drug price hike
Swiss pharmaceutical conglomerate Novartis has announced it will pause scheduled drug price increases for the remainder of 2018, alongside reporting its positive second quarter (Q2) earnings and updating full year...
-
19 July 2018
Roche gains FDA breakthrough status for Tecentriq combination
Roche has obtained breakthrough therapy designation from the US Food and Drug Administration (FDA) for the combination of Tecentriq (atezolizumab) with Avastin (bevacizumab) to treat hepatocellular carcinoma (HCC), the most...
-
19 July 2018
Roivant launches new startup Sinovant Sciences in China
Global healthcare company Roivant Sciences has launched a spin-off called Sinovant Sciences in Shanghai, China, to primarily develop innovative therapeutics through biomedical research and development (R&D).
-
19 July 2018
Sanofi and Revolution Medicines partner to develop cancer treatments
Sanofi has formed an alliance with US-based drug discovery company Revolution Medicines to develop and commercialise potential treatments for non-small lung cancer and other types of cancer involving certain mutations.
